Internal Medicine, Hematology & Oncology · Boulder, CO
NPI
1346224664
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
4715 Arapahoe Ave
Boulder, CO, 80303
Phone (303) 385-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.9M
72,921 services
Medicare patients, 2024
586
Average age 74
Drug cost, 2024
$3.0M
1,345 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark A Sitarik was code J9271 (injection, pembrolizumab, 1 mg), 7,700 times for 16 patients. In total Mark A Sitarik billed 72,921 services in 138 codes, and Medicare paid $1.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-07-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 7,700 | 16 | $44.62 | $344K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 7,020 | 21 | $39.32 | $276K |
| J9267 Injection, paclitaxel, 1 mg | Office | 3,270 | 17 | $0.08 | $273 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 3,150 | 18 | $0.11 | $348 |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2,470 | 17 | $36.81 | $91K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,600 | 15 | $15.93 | $25K |
| Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 1,140 | 12 | $16.55 | $19K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 983 | 54 | $0.09 | $87.68 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 680 | 34 | $0.26 | $177 |
| 99213 Office E&M - Established | Office | 619 | 287 | $65.18 | $40K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 470 | 37 | $0.67 | $314 |
| 99214 Office E&M - Established | Office | 259 | 127 | $97.17 | $25K |
| J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | Office | 227 | 13 | $2.70 | $613 |
| 96413 Chemotherapy Administration | Office | 198 | 106 | $102.91 | $20K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 197 | 166 | $12.62 | $2,487 |
By year: 2022 $1.3M for 78,372 services; 2023 $1.4M for 74,120 services; 2024 $1.9M for 72,921 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark A Sitarik prescribed most often to Medicare patients was Anastrozole, with 100 prescriptions and refills. In total Mark A Sitarik wrote 1,345 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 100 | 257 | 31 | $2,657 |
| Eliquis Apixaban | 64 | 118 | 15 | $66K |
| Lorazepam Generic | 60 | 75 | 18 | $396 |
| Hydroxyurea Generic | 53 | 123 | 12 | $1,429 |
| Acyclovir Generic | 52 | 72 | Under 11 | $844 |
| Prednisone Generic | 46 | 70 | 13 | $243 |
| Dexamethasone Generic | 41 | 42 | 11 | $477 |
| Gabapentin Generic | 37 | 72 | 11 | $981 |
| Xtandi Enzalutamide | 36 | 36 | Under 11 | $511K |
| Imatinib Mesylate Generic | 33 | 35 | Under 11 | $94K |
| Levothyroxine Sodium Generic | 32 | 44 | Under 11 | $340 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 31 | 31 | 15 | $467 |
| Warfarin Sodium Generic | 30 | 56 | Under 11 | $169 |
| Xarelto Rivaroxaban | 25 | 70 | Under 11 | $38K |
| Morphine Sulfate Er Morphine Sulfate | 23 | 23 | Under 11 | $603 |
Brand drugs: - claims; generic drugs: 1,028 claims; opioid claims: 100.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Mark A Sitarik were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.